Teva Pharmaceutical Industries, Ltd.: Asthma trials

The registry lists 54 Asthma studies with Teva Pharmaceutical Industries, Ltd. as lead sponsor. 0 are open to participants now and 36 have results posted.

Phase 1 5Phase 2 11Phase 3 30Phase 4 6No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Test if TEV-53275 is Effective in Relieving AsthmaTerminatedNCT04847674Phase 2Results posted
• A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With AsthmaCompletedNCT04677959Phase 4Results posted
• A Study to Test if TEV-48574 is Effective in Relieving AsthmaTerminatedNCT04545385Phase 2Results posted
• A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With AsthmaCompletedNCT03890666Phase 4Results posted
• Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With AsthmaCompletedNCT03756883Phase 3Results posted
• A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic AsthmaTerminatedNCT03052725Phase 3Results posted
• Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder InhalerCompletedNCT02980133Phase 3Results posted
• A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With AsthmaCompletedNCT02969408Phase 3Results posted
• An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway InflammationTerminatedNCT02937168Phase 4Results posted
• Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent AsthmaCompletedNCT02513160Phase 3Results posted
• An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood EosinophilsCompletedNCT02501629Phase 3Results posted
• Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic ParticipantsCompletedNCT02495168Phase 3Results posted
• Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood EosinophilsCompletedNCT02452190Phase 3Results posted
• Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent AsthmaCompletedNCT02175771Phase 3Results posted
• Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent AsthmaCompletedNCT02141854Phase 3Results posted
• Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent AsthmaCompletedNCT02139644Phase 3Results posted
• A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric AsthmaticsCompletedNCT02126839Phase 3Results posted
• Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With AsthmaCompletedNCT02062463Phase 3Results posted
• A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent AsthmaCompletedNCT02040779Phase 3Results posted
• A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent AsthmaCompletedNCT02040766Phase 3Results posted
• A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent AsthmaCompletedNCT02031640Phase 3Results posted
• Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric PatientsCompletedNCT01899144Phase 2Results posted
• Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)CompletedNCT01857323Phase 3Results posted
• Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER®CompletedNCT01803555Phase 3Results posted
• Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma SubjectsCompletedNCT01772368Phase 2Results posted
• Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State PharmacokineticsCompletedNCT01747629Phase 3Results posted
• Safety Study of Albuterol Spiromax® in Subjects With AsthmaCompletedNCT01698320Phase 3Results posted
• A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma MedicationsCompletedNCT01576718Phase 2Results posted
• A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing SteroidsCompletedNCT01479621Phase 2Results posted
• A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent AsthmaCompletedNCT01424813Phase 3Results posted
• A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed DosingTerminatedNCT01218009Phase 3Results posted
• A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent AsthmaCompletedNCT01058863Phase 2Results posted
• Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled AsthmaCompletedNCT00587288Phase 2Results posted
• Albuterol HFA MDI in Pediatric Participants With AsthmaCompletedNCT00577655Phase 3Results posted
• Comparison of Single-Dose Efficacy of an Albuterol Breath-Actuated Inhaler (Albuterol-HFA-BAI) Versus an Albuterol Metered-Dose Inhaler (Albuterol-HFA-MDI) in Participants With AsthmaCompletedNCT00530062Phase 4Results posted
• Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric AsthmaticsCompletedNCT00308685Phase 3Results posted
• A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With AsthmaCompletedNCT06664619Phase 3
• Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years OldCompletedNCT06290102Phase 1
• A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma ExacerbationsActive, not recruitingNCT06052267Phase 3
• Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcgCompletedNCT03879837Phase 3
• A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With AsthmaCompletedNCT02680561Phase 1
• Randomized, Placebo-controlled Study Comparing Efficacy of Fluticasone/Salmeterol Combination to Advair in AsthmaticsWithdrawnNCT02496715Phase 3
• Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and OlderCompletedNCT02437604Phase 1
• Study in Patients' With Persistent Asthma and Chronic Obstructive Pulmonary DiseaseCompletedNCT02419872
• Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients With AsthmaCompletedNCT01844401Phase 1
• A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)CompletedNCT01302587
• A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)CompletedNCT01056159Phase 1
• Non-invasive Measures of Distal Lung Disease in AsthmaticsCompletedNCT00250341Phase 4
• Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild Allergic AsthmaCompletedNCT00232999Phase 2
• Comparison of Two Bronchodilator Inhalers in Pediatric AsthmaticsCompletedNCT00112411Phase 2
• Evaluation of Two Doses of QVAR Versus Placebo by Breath Operated and Metered Dose Inhalers in Moderate Asthmatic Adolescents and Adults on a Stable Regimen of Inhaled CorticosteroidsCompletedNCT00109668Phase 3
• Evaluation of Two Doses of QVAR by Breath Operated and Metered Dose Inhalers in Asthmatic ChildrenCompletedNCT00094016Phase 3
• Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents/Adult PatientsTerminatedNCT00071552Phase 4
• Comparative Effectiveness of a Breath-operated Albuterol Inhaler in Asthma Patients With Poor Inhaler TechniqueCompletedNCT00054964Phase 2